Comparative Effects of Low and High Doses of the
Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on
Morbidity and Mortality in Chronic Heart Failure
by Milton Packer, Philip A. Poole-Wilson, Paul W. Armstrong, John G. F. Cleland,
John D. Horowitz, Barry M. Massie, Lars Rydén, Kristian Thygesen, and Barry F.
Uretsky
Circulation
Volume 100(23):2312-2318
December 7, 1999
Copyright © American Heart Association, Inc. All rights reserved.
Kaplan-Meier analysis showing time to death in the low-dose and high-dose lisinopril groups.
Milton Packer et al. Circulation. 1999;100:2312-2318
Copyright © American Heart Association, Inc. All rights reserved.
High-dose:low-dose hazard ratios for all-cause mortality (left) and for death or hospitalization for
any reason (right) in patient subgroups defined by 5 pretreatment characteristics.
Milton Packer et al. Circulation. 1999;100:2312-2318
Copyright © American Heart Association, Inc. All rights reserved.
Kaplan-Meier analysis showing time to death or hospitalization for any reason in the low-dose
and high-dose groups.
Milton Packer et al. Circulation. 1999;100:2312-2318
Copyright © American Heart Association, Inc. All rights reserved.